Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COUNTERFEIT OVULEN-21 RESURFACES IN FOXMEYER WAREHOUSE, CUSTOMER PHARMACIES, HHS

Executive Summary

COUNTERFEIT OVULEN-21 RESURFACES IN FOXMEYER WAREHOUSE, CUSTOMER PHARMACIES, HHS announced in a Sept. 27 press release. According to the release, FDA has advised consumers in Texas and Oklahoma that counterfeit Ovulen-21 contraceptive tablet refills bearing the lot number -489 have been found in distribution in the two states. "FoxMeyer officials say they do not know how ]the[ suspect product came into its possession. . .but 50 counterfeit Ovulen-21 refills with the -489 lot number have been located in FoxMeyer-supplied pharmacies in the two states and five cartons were found in a FoxMeyer warehouse," HHS reported. Searle recalled two lots of Ovulen-21 (441 and 489) last November after the company and FDA were alerted that counterfeit versions of the contraceptive were in trade channels ("The Pink Sheet" Nov. 5, 1984 T&G-3). Like the products first recalled by Searle, the second batch of counterfeits has been found to be subpotent. Searle told whslrs. in November that counterfeit Ovulen lot 441 was in distribution in 1984 by Interstate Drug Exchange of Plainview, New York, and from Interstate to other unauthorized whslrs. According to HHS, none of the two suspect lots were found in FoxMeyer's possession last fall.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel